Dermagraft

Dermagraft

fibroblast-derived dermal replacement wound dressing
References in periodicals archive ?
8, 2015 /PRNewswire/ -- Three new real-world, comparative effectiveness analyses reporting the clinical outcomes of Apligraf for the treatment of hard-to-heal venous leg ulcers (VLUs), and Dermagraft for the treatment of chronic diabetic foot ulcers (DFUs), were recently presented at the Fall Symposium for Advanced Wound Care (SAWC) annual medical meeting in Las Vegas, Nev.
exclude the DERMAGRAFT business as discontinued operations.
2bn acquisition of ViroPharma and the disposal of Dermagraft, hinted that it had been a good year.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today releases historical income statements on both a US GAAP and Non GAAP basis for 2012 and the nine months ended September 30, 2013, recast to show the impact of DERMAGRAFT operations as discontinued.
Shire plc, the global specialty biopharmaceutical company, today announced that it has entered into a definitive agreement pursuant to which it has sold its DERMAGRAFT assets to Organogenesis Inc.
Over the past few years, the center has added a new technology to its wound-fighting arsenal--a procedure called Dermagraft.
Medical devices maker Smith & Nephew has dropped its skin product Dermagraft as it revealed weaker revenues and profits growth.
Smith & Nephew pic, Largo, FL and Advanced Tissue Sciences, La Jolla, CA announced that Dermagraft Human Fibroblast-Derived Skin Substitute has received an Ambulatory payment Classification (APC) pass-through code under the Hospital Outpatient Prospective Payment System from the Centers for Medicare & Medicaid Services (CMS - formerly HCFA).
The company, through its Dermagraft Joint Venture with Smith & Nephew, currently has two products on the market, TransCyte(TM), a temporary covering for third-degree (full- thickness) and second-degree (partial-thickness) burns, and Dermagraft, a living dermal replacement for the treatment of diabetic foot ulcers (currently available in Canada and the United Kingdom).
will highlight its growing portfolio of advanced wound care products and present the results of real-world, comparative effectiveness analyses, demonstrating the effectiveness of its Apligraf and Dermagraft living cell-based therapies, compared to Epifix, Primatrix and Theraskin, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, being held September 26-28, 2015 in Las Vegas, Nev.
Historical income statements recast for DERMAGRAFT discontinued